title: Reduced cell surface expression of CCR5 in CCR5Delta 32 heterozygotes is mediated by gene dosage, rather than by receptor sequestration.
abstract: Macrophage tropic (M-tropic) human immunodeficiency virus (HIV) infection of primary human T cells and macrophages requires optimal cell surface expression of the chemokine receptor CCR5 in addition to CD4. Natural mutations of CCR5 that impair surface expression bestow in the homozygous state complete resistance to M-tropic HIV infection. ccr5Delta32 is the major prototype of such mutants. ccr5Delta32 heterozygosity is associated with delayed onset of AIDS and reduced risk of initial transmission, and this correlates with reduced levels of CCR5 and reduced infectability of CD4+ cells. In addition to gene dosage, sequestration of wild type (WT) CCR5 by mutant protein has been proposed as a mechanism to explain reduced surface expression of CCR5 in cells from ccr5Delta32 and CCR5-893(-) heterozygotes. However, here we demonstrate that a molar excess of ccr5Delta32 or related deletion mutants does not significantly impair the cell surface density of co-expressed WT receptor either in human epithelial cells or Jurkat T cells. Further, ligand-dependent signaling and M-tropic HIV usage of WT receptor are also unaffected. Nascent WT receptor does associate with ccr5Delta32 and related mutant proteins and with other unrelated CC and CXC chemokine receptors under transient labeling conditions. However, using confocal microscopy, we demonstrate that in the steady state, WT and truncated CCR5 proteins segregate into nonoverlapping subcellular compartments. These findings together with the observed and known variability in the cell surface density of CCR5 on quiescent PBLs lead us to conclude that reduced CCR5 gene dosage rather than receptor sequestration is the major determinant of reduced CCR5 expression in cells from ccr5Delta32 heterozygotes.
authors.affiliation: Laboratory of Molecular Microbiology and Laboratory of Host Defenses, NIAID, National Institutes of Health, Bethesda, Maryland 20892, USA. aradhana@helix.nih.gov
authors.forename: Sundararajan
authors.initials: S
authors.lastname: Venkatesan
authors.forename: Ana
authors.initials: A
authors.lastname: Petrovic
authors.forename: Donald I
authors.initials: DI
authors.lastname: Van Ryk
authors.forename: Massimo
authors.initials: M
authors.lastname: Locati
authors.forename: Drew
authors.initials: D
authors.lastname: Weissman
authors.forename: Philip M
authors.initials: PM
authors.lastname: Murphy
mesh_terms: D000595:Amino Acid Sequence; D002460:Cell Line; D002462:Cell Membrane / Q000378:metabolism; D005434:Flow Cytometry; D018628:Gene Dosage; D006678:HIV / Q000378:metabolism; D006579:Heterozygote; D006720:Homozygote; D006801:Humans; D008969:Molecular Sequence Data; D009154:Mutation; D019713:Receptors, CCR5 / Q000235:genetics / Q000378:metabolism*; D017384:Sequence Deletion
chemical_list: D019713:Receptors, CCR5